Discovery of orally bioavailable cathepsin S inhibitors for the reversal of neuropathic pain

Osamu Irie*, Takatoshi Kosaka, Takeru Ehara, Fumiaki Yokokawa, Takanori Kanazawa, Hajime Hirao, Astuko Iwasaki, Junichi Sakaki, Naoki Teno, Yuko Hitomi, Genji Iwasaki, Hiroaki Fukaya, Kazuhiko Nonomura, Keiko Tanabe, Shinichi Koizumi, Noriko Uchiyama, Stuart J. Bevan, Marzia Malcangio, Clive Gentry, Alyson J. FoxMohammed Yaqoob, Andrew J. Culshaw, Allan Hallett

*Corresponding author for this work

Research output: Journal Publications and ReviewsRGC 21 - Publication in refereed journalpeer-review

35 Citations (Scopus)

Abstract

Cathepsin S inhibitors are well-known to be an attractive target as immunological therapeutic agents. Recently, our gene expression analysis identified that cathepsin S inhibitors could also be effective for neuropathic pain. Herein, we describe the efficacy of selective cathepsin S inhibitors as antihyperalgesics in a model of neuropathic pain in rats after oral administration. © 2008 American Chemical Society.
Original languageEnglish
Pages (from-to)5502-5505
JournalJournal of Medicinal Chemistry
Volume51
Issue number18
DOIs
Publication statusPublished - 25 Sept 2008
Externally publishedYes

Fingerprint

Dive into the research topics of 'Discovery of orally bioavailable cathepsin S inhibitors for the reversal of neuropathic pain'. Together they form a unique fingerprint.

Cite this